Cargando…
Pathogen-Targeted Clinical Development to Address Unmet Medical Need: Design, Safety, and Efficacy of the ATTACK Trial
There is a crucial need for novel antibiotics to stem the tide of antimicrobial resistance, particularly against difficult to treat gram-negative pathogens like Acinetobacter baumannii-calcoaceticus complex (ABC). An innovative approach to addressing antimicrobial resistance may be pathogen-targeted...
Autores principales: | Watkins, Richard R, Du, Bin, Isaacs, Robin, Altarac, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150271/ https://www.ncbi.nlm.nih.gov/pubmed/37125468 http://dx.doi.org/10.1093/cid/ciad097 |
Ejemplares similares
-
Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections
por: Watkins, Richard R, et al.
Publicado: (2023) -
The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex
por: O’Donnell, John P, et al.
Publicado: (2023) -
Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species
por: Papp-Wallace, Krisztina M, et al.
Publicado: (2023) -
Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections
por: Shields, Ryan K, et al.
Publicado: (2023) -
Global Epidemiology and Mechanisms of Resistance of Acinetobacter baumannii-calcoaceticus Complex
por: Castanheira, Mariana, et al.
Publicado: (2023)